Hormone replacement therapy as treatment of breast cancer- a phase II study of Org OD 14 (tibilone)
1996

Hormone Replacement Therapy for Breast Cancer

Sample size: 14 publication Evidence: low

Author Information

Author(s): MER O'Brien, A Montes, TJ Powles

Primary Institution: Royal Marsden Hospital

Hypothesis

Can Org OD 14 (tibilone) be an effective treatment for post-menopausal women with advanced breast cancer who have failed tamoxifen therapy?

Conclusion

The study found that Org OD 14 showed limited effectiveness, with only one patient responding to treatment.

Supporting Evidence

  • One patient had a partial response lasting over 6 months.
  • Vaginal bleeding occurred in four patients, indicating significant toxicity.
  • All patients stopped treatment due to progressive disease.

Takeaway

This study tested a new drug for women with breast cancer who didn't respond to another treatment, but it only helped one person.

Methodology

This was a phase II study involving 14 post-menopausal women with advanced breast cancer who had previously failed tamoxifen treatment.

Limitations

The study had a small sample size and observed significant toxicity, including vaginal bleeding.

Participant Demographics

All participants were post-menopausal women with a median age of 63 years.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication